Margaret L Griffin1, Katherine A McDermott2, R Kathryn McHugh3, Garrett M Fitzmaurice4, Robert N Jamison5, Roger D Weiss6. 1. Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: mgriffin@mclean.harvard.edu. 2. Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA. Electronic address: katherine.a.mcdermott@gmail.com. 3. Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: kmchugh@mclean.harvard.edu. 4. Laboratory for Psychiatric Biostatistics, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Biostatistics, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA. Electronic address: gfitzmaurice@partners.org. 5. Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: rjamison@partners.org. 6. Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: rweiss@mclean.harvard.edu.
Abstract
BACKGROUND: Patients with prescription opioid use disorder commonly report relief of chronic pain as the chief reason for first opioid use; indeed, the prevalence of chronic pain is high in this population. Understanding the association between pain severity and subsequent opioid use is crucial for understanding how to manage these conditions simultaneously and has not been examined in this population. The aim of this analysis was to examine the proximal effect of pain severity on opioid use during 12 weeks of buprenorphine-naloxone therapy for patients with chronic pain and prescription opioid use disorder. METHODS: This study is a secondary analysis of a national, randomized, controlled trial of buprenorphine-naloxone plus counseling for prescription opioid dependent patients. The association between past-week pain severity and opioid use in the subsequent week was examined in 148 patients presenting with chronic pain at baseline. RESULTS: Results from a multivariable logistic regression model showed that greater pain severity in a given week was significantly associated with increased odds of opioid use in the following week over the 12-week treatment, even after adjusting for covariates associated with opioid use (aOR=1.15, p<0.001). CONCLUSIONS: Despite previous reports of no association between baseline pain and subsequent opioid use, our findings suggest that patients who experience flare-ups of pain during treatment are prone to relapse to opioid use. Future studies may identify those who are at risk to use opioids by carefully monitoring patterns of their pain intensity over time.
RCT Entities:
BACKGROUND:Patients with prescription opioid use disorder commonly report relief of chronic pain as the chief reason for first opioid use; indeed, the prevalence of chronic pain is high in this population. Understanding the association between pain severity and subsequent opioid use is crucial for understanding how to manage these conditions simultaneously and has not been examined in this population. The aim of this analysis was to examine the proximal effect of pain severity on opioid use during 12 weeks of buprenorphine-naloxone therapy for patients with chronic pain and prescription opioid use disorder. METHODS: This study is a secondary analysis of a national, randomized, controlled trial of buprenorphine-naloxone plus counseling for prescription opioid dependent patients. The association between past-week pain severity and opioid use in the subsequent week was examined in 148 patients presenting with chronic pain at baseline. RESULTS: Results from a multivariable logistic regression model showed that greater pain severity in a given week was significantly associated with increased odds of opioid use in the following week over the 12-week treatment, even after adjusting for covariates associated with opioid use (aOR=1.15, p<0.001). CONCLUSIONS: Despite previous reports of no association between baseline pain and subsequent opioid use, our findings suggest that patients who experience flare-ups of pain during treatment are prone to relapse to opioid use. Future studies may identify those who are at risk to use opioids by carefully monitoring patterns of their pain intensity over time.
Authors: Jennifer Sharpe Potter; Jessica A Dreifuss; Elise N Marino; Scott E Provost; Dorian R Dodd; Lindsay S Rice; Garrett M Fitzmaurice; Margaret L Griffin; Roger D Weiss Journal: J Subst Abuse Treat Date: 2014-08-02
Authors: Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: L N Robins; J Wing; H U Wittchen; J E Helzer; T F Babor; J Burke; A Farmer; A Jablenski; R Pickens; D A Regier Journal: Arch Gen Psychiatry Date: 1988-12
Authors: Jodie A Trafton; Elizabeth M Oliva; Doyanne A Horst; Jared D Minkel; Keith Humphreys Journal: Drug Alcohol Depend Date: 2004-01-07 Impact factor: 4.492
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: A Vania Apkarian; Yamaya Sosa; Beth R Krauss; P Sebastian Thomas; Bruce E Fredrickson; Robert E Levy; R Norman Harden; Dante R Chialvo Journal: Pain Date: 2004-03 Impact factor: 6.961
Authors: Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss Journal: Drug Alcohol Depend Date: 2013-01-18 Impact factor: 4.492